Attention Business/Financial Editors:

Advitech reports its 2007 fourth quarter and 2007 year-end results

TSX VENTURE EXCHANGE: AVI QUEBEC CITY, April 15 /CNW Telbec/ - Advitech Inc. ("Advitech" or the "Company") (TSX Venture Exchange: AVI) announces today its financial results for the fourth quarter of 2007 and for the year ended on December 31, 2007. << FOURTH QUARTER OF 2007 FINANCIAL HIGHLIGHTS: - Increased revenues by 107% to $405,576 for the fourth quarter of 2007, compared to $196,026 for the corresponding period in 2006. - Dermylex(R) sales were the major driver of the $209,550 revenues growth. - Reduced net loss by 64% to $140,381 for the fourth quarter of 2007, compared to $387,858 for the same period in 2006. The reduction of the net loss was generated by a reduction of expenses and the sales increase. 2007 YEAR-END FINANCIAL HIGHLIGHTS: - Increased revenues by 68% to $1,110,157 for the year ended on December 31, 2007, compared to $661,285 for the corresponding period in 2006. - Maintained net loss at $1,349,753 for the year ended on December 31, 2007, compared to $1,375,059 for the same period in 2006. FINANCIAL POSITION: - As at December 31, 2007, the Company had $1,158,459 cash on hand, compared to $601,375 as at December 31, 2006, an increase of $557,084 which results from the completion of the Company's financing plan in the first two quarters of 2007. - Moreover, the Company has also accepted, in the first quarter of 2008, a financing offer from its banking institution for a $500,000 bank loan, to be guaranteed by Investissement Qu?bec. Renaud Beauchesne, President and Chief Executive Officer stated that "the $448,872 revenues increase over the 2006 performance is mainly due by further markets development for Dermylex(R) in the US and in Europe." "For fiscal 2007, the net loss was 2% lower than the previous year. The 68% revenues increase was offset by an increase in operation expenses resulting from the addition of senior management, from additional resources invested to complete Dermylex(R) distribution network and from higher financial expenses related to the new financing activities", also added Mr. Beauchesne. "Management team is satisfied with the Company's accomplishments in 2007. During the past year, we have reached significant milestones by increasing Dermylex(R) distribution channel in several new and strategic markets, publishing promising results on Wound Healing, a new application derived out of a combination of both our XP-828L and our new IM platforms, and finally by consolidating the Company's financial structure", added Renaud Beauchesne. Following up upon the momentum created in the second half of 2006, Advitech concluded new marketing and distribution agreements for seven additional territories including the US and France, two very strategic markets for the commercialization of Dermylex(R), the Company's flagship product. The 2008 revenues are therefore expected to be higher than those of 2007, and, as was the case for 2006 and 2007, revenues are expected to be concentrated in the last two quarters of the fiscal year. New products introductions and launches are planned for the second and third quarter of 2008. Early in the first quarter of 2008, Advitech announced the positive results from a second pre-clinical study on Wound Healing & skin care applications. Management believes that Wound Healing & skin care fields will open a significant market opportunity for the Company by opening the Pharma market in addition to the nutraceutical market where has been the development of the Company since its inception. Selected financial information Years and quarters ended December 31 (In thousands of dollars, except per share amounts) ------------------------------------... Fourth Fourth Fiscal Fiscal Income Statements Quarter Quarter Year Year 2007 2006 2007 2006 ------------------------------------... Total revenues $ 406 $ 196 $ 1,110 $ 661 ------------------------------------... Net loss $ (140) $ (388) $(1,350) $(1,375) ------------------------------------... Net loss per share, basic and diluted $ (0.00) $ (0.01) $ (0.02) $ (0.02) ------------------------------------... Selected financial information As at December 31 (In thousands of dollars) ------------------------------------... Balance Sheets 2007 2006 ------------------------------------... Cash and cash equivalents $ 1,158 $ 601 ------------------------------------... Other current assets $ 903 $ 433 ------------------------------------... Long-term assets $ 181 $ 203 ------------------------------------... ------------------------------------... Current liabilities $ 423 $ 515 ------------------------------------... Long-term liabilities $ 1,710 $ 1,092 ------------------------------------... Shareholders' equity $ 109 $ (370) ------------------------------------... The 2007 fiscal year financial statements as well as the management's discussion and analysis of results of operations and financial condition are available on the Company's website at www.advitech.com. >>